12,372 trials
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 98; 38 Participants
Multiple System Atrophy
Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51
Seborrheic Dermatitis
Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia, BCR-ABL1-Like · Central Nervous System Leukemia
Primary: DFS of Non-DS HR Post-induction Patients Receiving Intrathecal (IT) Methotrexate (MTX) Compared With Patients Receiving Intrathecal Triple Therapy (ITT) on a Modified…
Complicated Intra-abdominal Infection
Primary: Number of Participants With Clinical Response at Test of Cure (TOC) Visit: Clinically Evaluable (CE) Analysis Set — 36; 4; 0 Participants
Covid19 · Multisystem Inflammatory Syndrome in Children (MIS-C)
Primary: Estimate the Proportion of Patients With Normal Perfusion Versus Area(s) of Hypoperfusion in Heart, Kidneys and/or Brain — 2; 1 Participants
Chronic Spontaneous Urticaria
Primary: Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months — 53; 11; 0; 13 Participants
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Primary: Event Free Survival (EFS) Per Blinded Central Assessment — 8.3; 2.0 months — p=<0.0001
Acute Respiratory Distress Syndrome
Primary: Time to Clinical Improvement or Hospital Discharge up to Day 28 — NA; 19.0; NA; 22.0 days
ASCVD · Elevated Cholesterol · Heterozygous Familial Hypercholesterolemia
Primary: Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk — 78.18; 79.07; 76.81; 78.43 Percentage of participants
Hemophilia A
Primary: Model-Based Annualized Bleeding Rate for Treated Bleeds — 27.0; 1.0; 1.0; 1.2 Treated bleeds per year — p=<0.0001
Infections, Meningococcal
Primary: Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M)…
Lung Cancer
Primary: Concordance — 91.3; 66.8; 82.7; 86.1 percentage of aggrement
Multiple Sclerosis · Infusion Reaction
Primary: Proportion of Participants With Infusion-related Reaction (IRR) on Day 0 — 5; 6 participnats
Attention Deficit Hyperactivity Disorder
Primary: Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score — -7.6; -2.1 score on a scale — p==.0106